Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Viking Announces Positive 52-Week Data from Phase 2b VOYAGE Study of VK2809 in NASH
Details : VK2809 is a novel liver-selective thyroid hormone receptor beta agonist, which is being evaluated in patients with biopsy-confirmed non-alcoholic steatohepatitis.
Product Name : VK2809
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 06, 2024
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Morgan Stanley
Deal Size : $632.5 million
Deal Type : Public Offering
Viking Therapeutics Closes Public Offering with Underwriters' Option Exercise
Details : The net proceeds will support the development of VK2809, a selective thyroid hormone receptor beta agonist, currently in Phase 2b trials for treating non-alcoholic steatohepatitis & fibrosis.
Product Name : VK2809
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
April 03, 2024
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Morgan Stanley
Deal Size : $632.5 million
Deal Type : Public Offering
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Morgan Stanley
Deal Size : $550.0 million
Deal Type : Public Offering
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
Details : Proceeds from the offering will support VK2809, a selective thyroid hormone receptor beta agonist under Phase 2b evaluation for treating non-alcoholic steatohepatitis and fibrosis.
Product Name : VK2809
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 28, 2024
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Morgan Stanley
Deal Size : $550.0 million
Deal Type : Public Offering
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Morgan Stanley
Deal Size : $350.0 million
Deal Type : Public Offering
Viking Therapeutics Announces Proposed Public Offering of Common Stock
Details : The net proceeds from the proposed offering will support VK2809, a selective thyroid hormone receptor beta agonist being developed for treating non-alcoholic steatohepatitis and fibrosis.
Product Name : VK2809
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 27, 2024
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Morgan Stanley
Deal Size : $350.0 million
Deal Type : Public Offering
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VK2809 novel liver-selective thyroid hormone receptor beta agonist,which is being evaluated for the treatment of patients with biopsy-confirmed non-alcoholic steatohepatitis.
Product Name : VK2809
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2023
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VK2809 is an orally available, selective agonist of the thyroid beta receptor, suggesting promising therapeutic potential in a range of lipid disorders. Drug is currently being evaluated in a Phase 2b clinical trial for biopsy-confirmed non-alcoholic ste...
Product Name : VK2809
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2023
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VK2809 is an orally available, selective agonist of the thyroid beta receptor, suggesting promising therapeutic potential in a range of lipid disorders. Drug is currently being evaluated for biopsy-confirmed non-alcoholic steatohepatitis.
Product Name : VK2809
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 16, 2023
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from the company's 12-week Phase 2 study of VK2809 in patients with non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C) will be presented at the Digital International Liver Congress™ 2020.
Product Name : VK2809
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 20, 2020
Lead Product(s) : VK2809
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable